Reversibly Immortalized Cell Lines for Anti-Senescence Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting anti-senescence or pro-senescence compounds are inefficient and labor-intensive, requiring complex cell line manipulation and animal sacrifice, limiting the number of compounds that can be tested effectively for their senescence-altering activities.
Innovation Solution
A novel in vitro method using reversibly immortalized cell lines lacking a functional Pten gene, which can be easily automated, involves bringing these cells back to a non-immortalized state and assessing cellular proliferation after exposure to candidate compounds, allowing for quick and inexpensive screening for anti-senescence or pro-senescence activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PtenLx/Lx MEF cells are infected with retro-viral Cre vectors to create Pten null cells for senescence screening, then the ability to detect anti-senescence compounds is improved, but the complexity of cell line preparation and the time required increases significantly
Solution Approach 1:
The patent applies preliminary action by pre-engineering cell lines with integrated Cre-loxP systems and doxycycline-inducible p53 expression before screening begins. This allows the senescence-inducing mechanism to be prepared in advance, eliminating the need for complex retroviral infections during the actual screening process. The cell lines are pre-configured to require only doxycycline addition to induce senescence, making the screening workflow simpler and more reproducible.
2Productivity
If PtenLx/Lx mice are continuously crossbred to obtain MEF cells for the assay, then the availability of cells for screening is maintained, but the time and resources required for animal husbandry and cell generation increase
Solution Approach 1:
The patent applies copying by creating immortalized cell lines that can be repeatedly passaged and used indefinitely without requiring continuous animal sacrifice. The engineered cell lines with integrated loxP sites and doxycycline-inducible p53 serve as reusable templates that can generate unlimited supplies of senescent and non-senescent cells through simple culture maintenance and doxycycline treatment, eliminating the need for continuous mouse breeding and tissue extraction.
3Reliability
If complex retroviral infection and selection procedures are used to create senescent cell models, then the accuracy of senescence induction is improved, but the ease of operation and accessibility of the method decreases
Solution Approach 1:
The patent applies taking out by extracting the complex retroviral infection and selection steps from the senescence induction process. Instead, the invention uses a simplified system where pre-engineered cell lines with integrated loxP sites and doxycycline-inducible p53 expression respond to doxycycline addition by inducing senescence through Cre-recombinase activation. This removes the need for multiple infection rounds, antibiotic selections, and viral production steps, making the method accessible to standard laboratory facilities.
4Measurement precision
If the screening method requires multiple steps of cell manipulation and regeneration, then the precision of senescence assessment is improved, but the productivity and speed of compound identification decreases
Solution Approach 1:
The patent applies dynamics by creating a reversible, inducible system where cell lines can dynamically switch between senescent and non-senescent states through doxycycline addition or removal. This dynamic control allows researchers to induce senescence only when needed for screening, maintain cells in a proliferative state for rapid compound testing, and quickly transition between conditions without lengthy regeneration steps. The system adapts its state based on experimental requirements, optimizing both precision and speed.
Data Source
AI summary
The present invention refers to a novel in vitro method for detecting anti-senescence or pro-senescence activity of a compound, and to compounds with anti-senescence activity detected by said method, in particular to Salvia Haenkei extracts, and to compositions comprising said extracts.